Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443014 | 1.00 | GLS (0.56) | GLSGABRA1GABRB2MTNR1AHRH3 | |
| SCHEMBL7289411 | 0.87 | GLS (0.57) | GLSGABRA1GABRB2MTNR1AHRH3 | |
| SCHEMBL7289417 | 0.87 | GLS (0.57) | GLSGABRA1GABRB2MTNR1AHRH3 | |
| SCHEMBL7290004 | 0.87 | GLS (0.57) | GLSGABRA1GABRB2MTNR1AHRH3 | |
| SCHEMBL12777934 | 0.84 | POLB (0.43) | GLSGABRA1GABRB2TP53MEN1 | |
| SCHEMBL13484526 | 0.84 | MIF (0.46) | GLSGABRA1GABRB2MEN1KMT2A | |
| SCHEMBL5847705 | 0.82 | POLB (0.42) | GLSGABRA1GABRB2MTNR1AMEN1 | |
| SCHEMBL20562936 | 0.82 | GLS (0.50) | GLSGABRA1GABRB2MAPTMEN1 | |
| SCHEMBL5847871 | 0.82 | POLB (0.42) | GLSGABRA1GABRB2MTNR1AMEN1 | |
| SCHEMBL5847707 | 0.82 | POLB (0.42) | GLSGABRA1GABRB2MTNR1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689639-B | Spirolactams as ROCK inhibitors | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | GLS 442/4885GABRA1 3183/4885GABRB2 3902/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | GLS 491/4885GABRA1 500/4885GABRB2 524/4885 |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | GLS 442/4885GABRA1 3183/4885GABRB2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.